Stay updated on Autogene Cevumeran Combo With Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Autogene Cevumeran Combo With Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the Autogene Cevumeran Combo With Pembrolizumab in Melanoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedThe page has updated the number of study locations from 37 to 41 and added specific locations in Georgia, Ohio, Germany, and Spain. Additionally, there are new dates related to the study's timeline.SummaryDifference5%
- Check42 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
- Check56 days agoChange DetectedThe study has been updated to include 37 locations, notably adding several sites in San Francisco and Madrid, while removing 57 previous locations including various sites across the United States and Europe.SummaryDifference15%
- Check63 days agoChange DetectedThe type of intervention has been updated from version v2.13.3 to v2.14.0.SummaryDifference0.3%
- Check93 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.1%
Stay in the know with updates to Autogene Cevumeran Combo With Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Autogene Cevumeran Combo With Pembrolizumab in Melanoma Clinical Trial page.